Trial Profile
WEUSKOP5522: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Fosdevirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 06 Jun 2017 Status changed from active, no longer recruiting to completed.
- 26 Jun 2014 Planned End Date changed from 1 Jul 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Planned primary completion date changed from 1 Jul 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.